Recent clinical trials have made significant strides in pediatric treatment for distinct conditions, showcasing the potential of tailored therapies. A phase 3 study on the use of low-dose and high-dose once-daily multimatrix mesalamine for children and adolescents with mild-to-moderate ulcerative colitis (UC) across North America, Europe, and the Middle East revealed a higher clinical response rate in the high-dose group during the acute phase, with no significant difference in maintenance efficacy between dosages, alongside a favorable safety profile. Concurrently, the ACcomplisH trial, a phase 2 investigation into TransCon CNP (navepegritide) for prepubertal children with achondroplasia, demonstrated that this novel prodrug of C-type natriuretic peptide (CNP) not only offers a safe treatment option but also improves growth velocity in a dose-dependent manner, particularly at higher doses. Both studies, despite focusing on different conditions, underline the importance of dose optimization in pediatric treatments and highlight the potential of novel therapeutic agents to significantly improve clinical outcomes in children with specific health conditions, emphasizing a move towards more effective and safer treatment protocols in pediatric medicine.